title: [High methotrexate doses in the treatment program for acute lymphoblastic leukemia and lymphosarcoma in children].
abstract: Tolerability and efficacy of high-dose methotrexate was studied in 70 pediatric patients with lymphoblastic tumors (acute lymphoblastic leukemia and non-Hodgkin's lymphoma). Methotrexate was given by 24-hour infusion of 500-1000 mg/m2 (total dose-700-3000 mg) after remission had been achieved. An antidote--calcium folinate--was administered 24 hours postinfusion. Major adverse side-effects involved were stomatitis, hepatotoxicity and fever. Survival in the study group was higher than in controls.
authors: L A
authors: LA
authors: Makhonova
authors: S A
authors: SA
authors: Maiakova
authors: A V
authors: AV
authors: Kiselev
authors: G A
authors: GA
authors: Gordina
authors: S A
authors: SA
authors: Balakirev
authors: I E
authors: IE
authors: Gavrilova
authors: E I
authors: EI
authors: Moiseenko
authors: O V
authors: OV
authors: Morozova
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007223:Infant; D002955:Leucovorin / Q000008:administration & dosage; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications / Q000188:drug therapy*; D011379:Prognosis; D012074:Remission Induction; D013997:Time Factors
chemical_list: D002955:Leucovorin; D008727:Methotrexate
vernacular_title: Povyshennye dozy metotreksata v programme lecheniia ostrogo limfoblastnogo leĭkoza i limfosarkomy u deteĭ.